UNSPSC 51263017: Zolertine hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H18N6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BM71FQZ25G, chemically known as piperazine, 1-phenyl-4-(2-(1h-tetrazol-5-yl)ethyl)- but more generally known as zolertine hydrochloride, which bears US NIH Compound Identifier 23669. Most nations, for tariff and trade purposes, schedule zolertine hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ZOLERTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Zolertine hydrochloride bears US NLM identifiers UMLS ID C2826060 and NCI Concept Code C82224. SMILES: C1CCC(CC1)N2CCN(CC2)CCC3[NH]NNN3.CL.

UNSPSC 51263017 Zolertine hydrochloride is a Commodity code with a significant mismatch between its nominal scope and recent state and local procurement activity. The code shows minimal relevant recent activity; the two opportunities posted under it involve naloxone procurement (an opioid antagonist unrelated to zolertine) and a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs. Neither opportunity directly solicits zolertine hydrochloride as a pharmaceutical product. State and local governments appear to tag pharmaceutical and pharmacy-related procurements under this code inconsistently, and the issuing bodies doing so represent health departments and health benefit agencies rather than a diverse municipal or county base.

Geographic activity is sparse and concentrated in the South. Seminole County, Florida and the Texas Health and Human Services Commission account for the two most recent postings, both from mid-2026. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) was exploratory in nature, gathering vendor capabilities for a potential direct-to-manufacturer prescription program rather than committing to specific product quantities or budget. Neither opportunity explicitly matched the zolertine commodity code name, suggesting that state and local procurement systems are applying the code label to broader pharmaceutical benefit management activity. Vendors pursuing work under this code should verify the actual product and service requirements in each solicitation, as the code's nominal pharmaceutical designation does not consistently align with posted opportunities.